Skip to main content
    D

    Dare Bioscience Inc (DARE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.58
    -0.07 (-11.13%)

    Market Cap: $12.93M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Dare Bioscience Inc (DARE) Financials: Revenue, Profit and Cash Flow

    Updated Aug 13, 2026. Financial statements from company filings, amounts in US dollars.

    Dare Bioscience reported revenue of $1.03M for the fiscal year ended Dec 31, 2025, up 10429.4% from the year before. That year, net income was -$13.40M with a net margin of -1300.7%, operating cash flow was -$9.89M and free cash flow was -$10.27M. The quarter ended Jun 30, 2026 had revenue of $187.55K and net income of -$2.98M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$1.03M+10429.4%71.3%-1315.5%-1300.7%
    Dec 2024$9.78K-99.7%100.0%-239692.2%-41430.9%
    Dec 2023$2.81M-71.9%100.0%-1101.9%-1074.2%
    Dec 2022$10.00MN/A100.0%-313.9%-309.5%
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$1.03M$9.78K$2.81M$10.00M$0$0$0$0$0$0
    Cost of revenue$295.80K$0$0$0$0$0$0$0$0$0
    Gross profit$734.39K$9.78K$2.81M$10.00M$0$0$0$0$0$0
    Research and development$5.52M$14.31M$21.54M$30.04M$30.62M$20.77M$8.55M$6.41M$984.75K$72.67K
    Operating income-$13.55M-$23.45M-$30.94M-$31.39M-$39.07M-$27.40M-$14.34M-$16.88M-$11.18M-$630.59K
    Net income-$13.40M-$4.05M-$30.16M-$30.95M-$38.70M-$27.40M-$14.26M-$16.74M-$11.50M-$672.69K
    EBITDA-$12.07M-$22.43M-$30.12M-$30.92M-$39.04M-$27.36M-$14.25M-$16.74MN/A-$630.59K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$187.55K$152.46K$1.02M$2.26K-$21.17K$0-$63.65K$41.69K$22.44K$9.30K$1.81M$1.00M
    Gross profit-$132.34K-$89.87K$727.88K$2.26K-$21.17K$0-$63.65K$41.69K$22.44K$9.30K$1.81M$1.00M
    Operating income-$2.97M-$3.00M-$1.47M-$3.67M-$3.83M-$4.58M-$5.39M-$4.68M-$7.36M-$6.02M-$5.17M-$8.40M
    Net income-$2.98M-$3.00M-$1.44M-$3.56M-$4.02M-$4.38M-$5.51M-$4.70M$12.91M-$6.76M-$5.06M-$8.30M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $2.10M by $22.61M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$32.47M$22.10M$21.28M$43.83M$55.81M$7.55M$7.44M$7.83M$14.26M$44.61K
    Current assets$27.06M$18.45M$17.54M$43.04M$55.30M$6.98M$6.44M$7.24M$8.35M$44.61K
    Cash and equivalents$24.71M$15.70M$10.48M$34.67M$51.67M$4.67M$4.78M$6.81M$7.56M$44.61K
    Total liabilities$29.63M$28.11M$26.33M$32.71M$17.05M$8.70M$7.00M$1.10M$967.04K$755.24K
    Short-term debt$2.10M$548.64K$468.73K$398.39K$270.55K$1.37M$0N/A$0$697.50K
    Long-term debtN/AN/AN/AN/AN/AN/AN/AN/A$0$4.44M
    Shareholder equity$2.84M-$6.01M-$5.05M$11.11M$38.75M-$1.15M$440.83K$6.73M$13.29M-$710.62K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$22.37M$27.83M$32.47M$30.75M$12.98M$18.62M$22.10M$18.06M$23.61M$13.01M$21.28M$25.05M
    Total liabilities$22.93M$27.09M$29.63M$27.89M$25.71M$28.18M$28.11M$19.54M$20.93M$24.01M$26.33M$27.34M
    Cash and equivalents$12.62M$18.52M$24.71M$23.08M$5.04M$10.33M$15.70M$11.23M$16.41M$3.63M$10.48M$13.89M
    Shareholder equity-$560.10K$734.45K$2.84M$2.86M-$12.73M-$9.56M-$6.01M-$1.48M$2.67M-$11.00M-$5.05M-$2.29M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$9.89M$5.47M-$38.86M-$18.09M-$28.76M-$25.23M-$13.32M-$10.27M-$2.54M-$372.30K
    Capital expenditures$385.28K$573.05K$629.43K$63.07K$14.52K$17.63K$0$11.84K$0$535.00K
    Free cash flow-$10.27M$4.90M-$39.49M-$18.15M-$28.78M-$25.25M-$13.32M-$10.28M-$2.54M-$907.30K
    Dividends paidN/AN/AN/AN/AN/A$6.86M$789.59MN/A$0$0
    Investing cash flow-$385.28K-$573.05K-$629.43K-$63.07K-$14.52K-$17.63K$6.14M-$518.84K$9.92M$0
    Financing cash flow$19.28M$354.52K$15.64M$1.34M$75.85M$25.13M$5.15M$10.11M$155.00K$197.50K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$6.78M-$5.52M$1.44M-$442.13K-$5.42M-$5.47M$5.31M-$5.92M$12.90M-$6.81M-$8.18M-$7.97M
    Capital expenditures$80.59K$0$206.64K$174.70K$153.40K$157.33K$562.85K$282.32K$285.23K$7.30K$607.33K$22.10K
    Free cash flow-$6.86M-$5.52M$1.24M-$616.84K-$5.57M-$5.63M$4.74M-$6.21M$12.62M-$6.82M-$8.79M-$8.00M
    Last 12 quarters

    Frequently Asked Questions About DARE

    What is Dare Bioscience's annual revenue?

    Dare Bioscience reported revenue of $1.03M for the fiscal year ended Dec 31, 2025.

    How fast is Dare Bioscience's revenue growing?

    Revenue was up 10429.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -53.1%.

    Is Dare Bioscience profitable?

    No. Dare Bioscience reported net income of -$13.40M for the fiscal year ended Dec 31, 2025, with a net margin of -1300.7%.

    How much free cash flow does DARE generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$9.89M minus capital expenditures of $385.28K produced free cash flow of -$10.27M.

    How much debt does Dare Bioscience have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $2.10M and cash and equivalents of $24.71M.